Wednesday, 18 June 2025
Trending

Cryptocurrency

Mirati Therapeutics price target lowered to $61 from $100 at BofA

Acorda Therapeutics stockholders approve Reverse Stock Split proposal




Previous Post

Jounce Therapeutics Presents INNATE Phase 1 and SELECT Clinical Trial data at the European Society of Medical Oncology Immuno-Oncology (ESMO – IO) Annual Congress



Next Post

Argus upgrades AT&T to Buy amid focus on wireless and broadband expansion



Source